Modulating pro-fibrotic macrophages using yeast beta-glucan microparticles prepared by Pressurized Gas eXpanded liquid (PGX) Technology

Pro-fibrotic M2-like macrophages are widely implicated in the pathogenesis and progression of lung fibrosis due to their production of pro-fibrotic growth factors and cytokines. Yeast beta-glucan (YBG) microparticles have shown potential as immunomodulators that can convert macrophage polarization f...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials Vol. 313; p. 122816
Main Authors: Naiel, S., Dowdall, N., Zhou, Q., Ali, P., Hayat, A., Vierhout, M., Wong, E.Y., Couto, R., Yépez, B., Seifried, B., Moquin, P., Kolb, M.R., Ask, K., Hoare, T.
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 01-02-2025
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pro-fibrotic M2-like macrophages are widely implicated in the pathogenesis and progression of lung fibrosis due to their production of pro-fibrotic growth factors and cytokines. Yeast beta-glucan (YBG) microparticles have shown potential as immunomodulators that can convert macrophage polarization from a pro-fibrotic phenotype to an anti-fibrotic phenotype through the engagement of the Dectin-1 receptor. However, the processing conditions used to fabricate YBG microparticles can lead to unpredictable immunomodulatory effects. Herein, we report the use of Pressurized Gas eXpanded liquids (PGX) Technology® to fabricate YBG (PGX-YBG) microparticles with higher surface areas, lower densities, and smaller and more uniform size distributions compared to commercially available spray-dried YBGs. PGX-YBG is shown to activate Dectin-1 more efficiently in vitro while avoiding significant TLR 2/4 activation. Furthermore, PGX-YBG microparticles effectively modulate M2-like fibrosis-inducing murine and human macrophages into fibrosis-suppressing macrophages both in vitro as well as in ex vivo precision-cut murine lung slices, suggesting their potential utility as a therapeutic for addressing a broad spectrum of fibrotic end-point lung diseases. [Display omitted] •Scalable production of high purity, highly porous yeast beta-glucan (PGX-YBG) microparticles.•Enhanced Dectin-1 activation compared to conventional spray dried YBG.•PGX-YBG preferentially taken up by pro-fibrotic macrophages.•Effective immunomodulation of human and murine macrophages in vitro and ex vivo.•Particle properties are conducive to effective lung delivery via inhalation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0142-9612
1878-5905
1878-5905
DOI:10.1016/j.biomaterials.2024.122816